💉Vaccine Efficacy Against Omicron Variant -Analysis Of UK Technical Briefing 31
On December 10th, 2021 the UK Health Security Agency released a technical briefing that presented current vaccine efficacy against the new SARS-CoV-2 variant OMICRON1. The following is a break down of some particulars from said briefing.
To begin, the briefing contained a case controlled design which measured protection of symptomatic COVID-19 in vaccinated individuals who received either two doses of AstraZeneca and Pfizer booster, or who received all 3 doses from Pfizer, then compared the effectiveness of both combinations against delta and omicron variants. Notably, calculations were based on 56,439 delta cases, and 581 omicron cases that were confirmed via RT-PCR testing. The results, detecting omicron wasn’t as simple compared to previous variants, and vaccine efficacy against the new variant waned. After reading this you will understand 3️⃣ things:
How testing for OMICRON was done in this case controlled design
If Pfizer and AstraZeneca are effective at preventing symptomatic COVID-19 from omicron variant
What all of that means for you and your family